CLDN18.2
Other names: Claudin 18.2, CLDN18.2 positivity
CLDN18.2 is a cell-surface protein that can be a marker for a targeted therapy category in stomach cancer.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
CLDN18.2 is a protein that is usually found in gastric cells and can also be found in gastric cancer cells. This examination assesses how much of this protein is visible in the tumor tissue.
Clinical meaning
CLDN18.2 status may make a specific category of antibody therapy worth discussing in advanced gastric cancer. Assessment thresholds and reporting standards are still evolving and may vary between facilities.
Testing methods
- CLDN18.2 immunohistochemistry
A staining test to assess CLDN18.2 expression in stomach cancer.
- Tumour tissue biopsy
Collection of tumour tissue to confirm the diagnosis and provide material for further testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Percentage and intensity of staining on the pathology report.
- Whether the laboratory uses the applicable thresholds in the relevant clinical trials.
- History of HER2 therapy if any, because the order of discussion may differ.
- Drug availability: some are still going through clinical trials.
Related drugs
- Zolbetuximab
Anti-CLDN18.2 monoclonal antibody
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Guides discussing this marker
- CLDN18.2-positive gastric cancer: what does the result mean?9 min read
- Understanding clinical trials: terms, phases, and how to check early fit7 min read
- Understanding biomarkers without heavy jargon7 min read
Written to help prepare questions and documents, not to replace a doctor's assessment.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT07872722Phase 2Combination regimen
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Stomach Cancer | biomarker: CLDN18.2 | Immunotherapy, Targeted therapy, Chemotherapy
Japan4 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker CLDN18.2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07872722Not verified
Check options based on your result
Share the CLDN18.2 result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Stomach Cancer
Cancer type
Reason: Related through a biomarker
- Gastric cancer after chemotherapy no longer gives results
Decision situation
Reason: Related through a biomarker
- CLDN18.2 positive (75 percent or more, 2+ intensity or higher)
Molecular alteration
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
- Zolbetuximab
Drug
Reason: Targets this marker
- CLDN18.2: China approved zolbetuximab for first line care - what it means for Indonesian patients
Explainer
Reason: Related to this page
To check
- Tumour tissue biopsy
Diagnostic test
Reason: Diperiksa melalui
- CLDN18.2 immunohistochemistry
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Complete pathway
CLDN18.2 in stomach cancer
A CLDN18.2 result is positive. What does it mean and what is worth discussing with the medical team?
- CLDN18.2 markerStarting point: what this marker shows and what it does not decide by itself.
- CLDN18.2 positiveWhat a positive result means under the pathology testing threshold.
- CLDN18.2 IHCA common testing method, including on stored tissue blocks.
- After chemotherapy stops workingThe decision situation when first-line therapy no longer controls the disease.
- ZolbetuximabAn anti-CLDN18.2 therapy approved in several countries and given with chemotherapy.
- Positive CLDN18.2 result guideMeaning of the result, approved options versus investigational ones, and questions for the doctor.
A structured summary so IHC results and treatment history are readable.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.